Skip to main content
. 2022 Aug 4;13:954268. doi: 10.3389/fimmu.2022.954268

Figure 3.

Figure 3

The subgroup analysis of adults and children in ORRs (A) and CRRs (B) at any time after ruxolitinib treatment in SR-aGVHD; The subgroup analysis of adults and children in ORRs (C) and CRRs (D) at any time after ruxolitinib treatment in SR-cGVHD.